Emerging molecular pathways and targets in neuroendocrine prostate cancer

M. Francesca Monn, Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng

Research output: Contribution to journalComment/debate

Abstract

Small cell prostate cancer remains a poorly understood, aggressive form of prostate cancer that develops either de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Frequently these tumors are advanced and are challenging to treat using current modalities. Research into molecular abnormalities that drive the development and propagation of small cell prostate cancer is ongoing and has the potential to revolutionize the management of these patients. Current research into the role of N-myc (NMYC) is altering our understanding of this aggressive disease. A recent study demonstrated that NMYC over expression can lead to development of invasive and androgen castrate resistant small cell prostate cancer. Furthermore, this research went on to show that NMYC over expression can lead to transformation of prostate adenocarcinoma into small cell prostate cancer. Finally, recent research has explored the role of aurora kinase A (AURKA) inhibitors in disrupting the NMYC pathway and providing a potential therapeutic target for treatment of small cell prostate cancer. As research continues to advance our understanding of the molecular underpinnings of small cell prostate cancer, we will be able to develop novel therapeutic targets and agents in order to better treat this aggressive form of prostate cancer.

Original languageEnglish (US)
Pages (from-to)S282-S285
JournalTranslational Cancer Research
Volume5
DOIs
StatePublished - 2016

Fingerprint

Prostatic Neoplasms
Research
Prostate
Adenocarcinoma
Aurora Kinase A
Androgens
Therapeutics
Neoplasms

Keywords

  • Molecular genetics
  • Molecular pathway/targets
  • N-myc (NMYC)
  • Neuroendocrine prostate cancer
  • Precision medicine
  • Prostate
  • Small cell prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Emerging molecular pathways and targets in neuroendocrine prostate cancer. / Monn, M. Francesca; Montironi, Rodolfo; Lopez-Beltran, Antonio; Cheng, Liang.

In: Translational Cancer Research, Vol. 5, 2016, p. S282-S285.

Research output: Contribution to journalComment/debate

Monn, M. Francesca ; Montironi, Rodolfo ; Lopez-Beltran, Antonio ; Cheng, Liang. / Emerging molecular pathways and targets in neuroendocrine prostate cancer. In: Translational Cancer Research. 2016 ; Vol. 5. pp. S282-S285.
@article{35b2eca8c3c246e583b1128d21bacc7a,
title = "Emerging molecular pathways and targets in neuroendocrine prostate cancer",
abstract = "Small cell prostate cancer remains a poorly understood, aggressive form of prostate cancer that develops either de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Frequently these tumors are advanced and are challenging to treat using current modalities. Research into molecular abnormalities that drive the development and propagation of small cell prostate cancer is ongoing and has the potential to revolutionize the management of these patients. Current research into the role of N-myc (NMYC) is altering our understanding of this aggressive disease. A recent study demonstrated that NMYC over expression can lead to development of invasive and androgen castrate resistant small cell prostate cancer. Furthermore, this research went on to show that NMYC over expression can lead to transformation of prostate adenocarcinoma into small cell prostate cancer. Finally, recent research has explored the role of aurora kinase A (AURKA) inhibitors in disrupting the NMYC pathway and providing a potential therapeutic target for treatment of small cell prostate cancer. As research continues to advance our understanding of the molecular underpinnings of small cell prostate cancer, we will be able to develop novel therapeutic targets and agents in order to better treat this aggressive form of prostate cancer.",
keywords = "Molecular genetics, Molecular pathway/targets, N-myc (NMYC), Neuroendocrine prostate cancer, Precision medicine, Prostate, Small cell prostate cancer",
author = "Monn, {M. Francesca} and Rodolfo Montironi and Antonio Lopez-Beltran and Liang Cheng",
year = "2016",
doi = "10.21037/tcr.2016.07.36",
language = "English (US)",
volume = "5",
pages = "S282--S285",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Emerging molecular pathways and targets in neuroendocrine prostate cancer

AU - Monn, M. Francesca

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

PY - 2016

Y1 - 2016

N2 - Small cell prostate cancer remains a poorly understood, aggressive form of prostate cancer that develops either de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Frequently these tumors are advanced and are challenging to treat using current modalities. Research into molecular abnormalities that drive the development and propagation of small cell prostate cancer is ongoing and has the potential to revolutionize the management of these patients. Current research into the role of N-myc (NMYC) is altering our understanding of this aggressive disease. A recent study demonstrated that NMYC over expression can lead to development of invasive and androgen castrate resistant small cell prostate cancer. Furthermore, this research went on to show that NMYC over expression can lead to transformation of prostate adenocarcinoma into small cell prostate cancer. Finally, recent research has explored the role of aurora kinase A (AURKA) inhibitors in disrupting the NMYC pathway and providing a potential therapeutic target for treatment of small cell prostate cancer. As research continues to advance our understanding of the molecular underpinnings of small cell prostate cancer, we will be able to develop novel therapeutic targets and agents in order to better treat this aggressive form of prostate cancer.

AB - Small cell prostate cancer remains a poorly understood, aggressive form of prostate cancer that develops either de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Frequently these tumors are advanced and are challenging to treat using current modalities. Research into molecular abnormalities that drive the development and propagation of small cell prostate cancer is ongoing and has the potential to revolutionize the management of these patients. Current research into the role of N-myc (NMYC) is altering our understanding of this aggressive disease. A recent study demonstrated that NMYC over expression can lead to development of invasive and androgen castrate resistant small cell prostate cancer. Furthermore, this research went on to show that NMYC over expression can lead to transformation of prostate adenocarcinoma into small cell prostate cancer. Finally, recent research has explored the role of aurora kinase A (AURKA) inhibitors in disrupting the NMYC pathway and providing a potential therapeutic target for treatment of small cell prostate cancer. As research continues to advance our understanding of the molecular underpinnings of small cell prostate cancer, we will be able to develop novel therapeutic targets and agents in order to better treat this aggressive form of prostate cancer.

KW - Molecular genetics

KW - Molecular pathway/targets

KW - N-myc (NMYC)

KW - Neuroendocrine prostate cancer

KW - Precision medicine

KW - Prostate

KW - Small cell prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84991818102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991818102&partnerID=8YFLogxK

U2 - 10.21037/tcr.2016.07.36

DO - 10.21037/tcr.2016.07.36

M3 - Comment/debate

VL - 5

SP - S282-S285

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

ER -